Sales performance reflected lower COVID-19 solutions sales versus Q1 2022. Excluding COVID-19 solutions, sales grew +10% CER with strong performance across Vaccines, Specialty and General Medicines. Total operating profit and total EPS performance reflected the comparison to Q1 2022 which included the one-off income benefit of the Gilead settlement and higher Xevudy sales. Cash generated from operations GBP 0.3 billion; free cash outflow (GBP 0.7) billion lower than Q1 2022 primarily due to Gilead settlement income received in Q1 2022 and timing of profit share payments. Emma Walmsley, Chief Executive Officer, GSK said, "We have made a strong start to 2023, with excellent performance across Vaccines, Specialty and General Medicines. We are very focused on our upcoming launches, including our potential RSV older adult vaccine, and on continuing to strengthen our pipeline – both organically with several positive late-stage read-outs already this year, and through targeted business development. This continued momentum is also supporting our confidence in delivering our medium and long-term growth ambitions."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- GSK says EMA validates marketing authorization application for Jemperli
- Bellus Health cut to Sector Perform at RBC Capital on GSK deal
- GSK to acquire Bellus Health for $14.75 per share
- Bellus Health Surges after Acquisition by GSK for $2 Billion
- GSK reports EAGLE-2 and EAGLE-3 phase III trials met primary endpoint
